CARDIOGENESIS' TRANSMYOCARDIAL REVASCULARIZATION SYSTEM PHASE I STUDY BEGINS; COMPANY EMPHASIZING LOW COST, PERCUTANEOUS CAPACITY OF HOLMIUM LASER
This article was originally published in The Gray Sheet
Executive Summary
CardioGenesis' transmyocardial revascularization Phase I clinical trial is "under way," company President and CEO Allen Hill said at the Piper Jaffray Medical Device Conference Feb. 6. One patient has been treated in the study, which will involve a total of 12 patients. Three U.S. and six European sites are expected to participate in the trial.